Drug firms await India court decision on patent protection

03/27/2013 | Economic Times (India), The

Pharmaceutical companies are awaiting a decision from India's Supreme Court, due April 1, that could determine the state of intellectual property protection for branded drugs in India. The case involves whether an amended form of Novartis' cancer treatment Glivec, used to treat chronic myeloid leukemia, is entitled to patent protection against generic competitors. "Big Pharma is nervous because nothing has gone in their favour in the recent past," said pharmaceutical consultant Ajay Kumar Sharma.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN